Futility stopping in clinical trials, optimality and practical considerations
- PMID: 32926648
- PMCID: PMC7954786
- DOI: 10.1080/10543406.2020.1818253
Futility stopping in clinical trials, optimality and practical considerations
Abstract
Stopping for futility is a useful tool in a clinical trial. It is widely used in single-arm trials in oncology and in many two-arm trials. We review three stopping rules for futility. We give recommendations for the optimal timing of futility looks in two-stage trials in terms of the information fraction and the probability of stopping under the alternative hypothesis. We discuss futility stopping in trials with substantial uncertainty about the variability of the outcome and in crossover trials.
Keywords: Simon’s design; crossover trial; futility stopping; phase 2 trial.
Figures

References
-
- Chen TT 1997. Optimal three-stage designs for phase II cancer clinical trials. Statistics in Medicine. 16: 2701–2711. - PubMed
-
- He P, Lai TL, and Liao OY. 2012. Futility stopping in clinical trials. Statistics and Its Interface 5 (4):415–423. doi: 10.4310/SII.2012.v5.n4.a4. - DOI
-
- Herring WJ, Liu K, Hutzelmann J, Snavely D, Snyder E, Ceesay P, Lines C, Michelson D, and Roth T. 2013. Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study. Sleep Medicine 14 (10):955–963. doi: 10.1016/j.sleep.2013.04.010. - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical